Patents by Inventor Minsheng Zhang

Minsheng Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200354349
    Abstract: A benzofuran derivative, a preparation method thereof and a use thereof in medicine are described. In particular, a benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, are described.
    Type: Application
    Filed: July 22, 2020
    Publication date: November 12, 2020
    Inventors: Biao LU, Xiaodong SHEN, Mingxun HE, Dong LIU, Minsheng ZHANG
  • Patent number: 10759787
    Abstract: The present invention relates to a benzofuran derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to the benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, wherein the definitions of the substituents in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: September 1, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Biao Lu, Xiaodong Shen, Mingxun He, Dong Liu, Minsheng Zhang
  • Patent number: 10323037
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 18, 2019
    Assignee: JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Dong Liu, Minsheng Zhang, Qiyue Hu
  • Patent number: 10302471
    Abstract: A device for observing the changes in abyssal flow based on differential pressure measurement, includes differential pressure sensing chamber and base connected through communicating portion, controller provided inside communicating portion, floating body and releasing device. Floating body is located on differential pressure sensing chamber and retracted through releasing device. Sensing chamber includes ambient water pressure chamber in communication with hydrostatic pressure chamber. Communicating portion is blocked by spring sheet. The spring sheet is provided with optical fiber sensor. Hydrostatic pressure chamber is always in communication with seawater, and ambient water pressure chamber is always in communication with water in abyssal sedimentary layer. Releasing device includes electric winch provided with acoustic signal device. Base is provided with earth pressure sensor and weight member. Optical fiber sensor, acoustic signal device, and earth pressure sensor are connected with controller.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: May 28, 2019
    Assignee: OCEAN UNIVERSITY OF CHINA
    Inventors: Tao Liu, Guanli Wei, Lei Guo, Xiuqing Yang, Xiujun Guo, Dong Wang, Yonggang Jia, Minsheng Zhang, Qingsheng Meng, Xiaolei Liu, Yongmao Zhu, Jia Xin
  • Publication number: 20190144751
    Abstract: Provide are a liquid crystal compound represented by formula I, and a liquid crystal mixture comprising the compound A lateral trifluoromethyl-containing liquid crystal compound having the structural characteristics of Formula I not only has a negative dielectric anisotropy (??), an appropriate optical anisotropy (?n), a higher clearing point (CP), a prominent low-temperature miscibility with other liquid crystals, and a low rotary viscosity (?1), but also has a good stability to UV and high temperatures, particularly, a negative dielectric anisotropy. Same can be applied to the formulation of liquid crystal compositions of positive and negative types, and it is particularly prominent that same has the advantages of a good solubility at low temperatures and a high transmittance.
    Type: Application
    Filed: October 18, 2018
    Publication date: May 16, 2019
    Inventors: Zhian LIANG, Wei ZHANG, Kai XU, Kui WANG, Yang XIANG, Shen YUAN, Minsheng GUO, Limei ZHANG
  • Patent number: 10144737
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: December 4, 2018
    Assignee: JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Minsheng Zhang, Yinfa Yan
  • Publication number: 20180327394
    Abstract: The present invention relates to a benzofuran derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to the benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, wherein the definitions of the substituents in the general formula (I) are the same as those defined in the description.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 15, 2018
    Inventors: Biao LU, Xiaodong SHEN, Mingxun HE, Dong LIU, Minsheng ZHANG
  • Publication number: 20180251465
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Application
    Filed: February 27, 2018
    Publication date: September 6, 2018
    Applicant: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Dong LIU, Minsheng ZHANG, Qiyue HU
  • Patent number: 9951077
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: April 24, 2018
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Dong Liu, Minsheng Zhang, Qiyue Hu
  • Publication number: 20170152264
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Application
    Filed: October 20, 2014
    Publication date: June 1, 2017
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Dong LIU, Minsheng ZHANG, Qiyue HU
  • Publication number: 20170114063
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Application
    Filed: October 20, 2014
    Publication date: April 27, 2017
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Minsheng Zhang, Yinfa YAN
  • Patent number: 9458140
    Abstract: The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: October 4, 2016
    Assignee: Eternity Bioscience Inc.
    Inventors: Dong Liu, Minsheng Zhang
  • Publication number: 20160257676
    Abstract: The present invention provides novel aminoisoquinoline compounds as defined in the specification, compositions thereof use of these compounds as protein kinase inhibitors and as therapeutic agents for treatment of Raf kinase, in particular BRAFV600E kinase, related diseases or disorders, such as cancers. In addition, the invention also includes methods and processes for preparing these novel aminoisoquinoline compounds.
    Type: Application
    Filed: September 12, 2013
    Publication date: September 8, 2016
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Minsheng Zhang, Dong Liu, Biao Lu
  • Publication number: 20160096825
    Abstract: The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds.
    Type: Application
    Filed: May 8, 2014
    Publication date: April 7, 2016
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Dong Liu, Minsheng Zhang
  • Patent number: 9090568
    Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: July 28, 2015
    Assignee: IMPACT Therapeutics, Inc.
    Inventors: Dong Liu, Minsheng Zhang, Kan He, Lianshan Zhang
  • Patent number: 8951993
    Abstract: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: February 10, 2015
    Assignee: Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Inventors: Baihua Hu, Kan He, Minsheng Zhang
  • Publication number: 20140031358
    Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.
    Type: Application
    Filed: March 12, 2012
    Publication date: January 30, 2014
    Applicant: Eternity Bioscience Inc.
    Inventors: Dong Liu, Minsheng Zhang, Kan He, Lianshan Zhang
  • Patent number: 8263659
    Abstract: A method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described in the general formula I below is administered in a therapeutically effective amount:
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: September 11, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Denis E. Ryono, Jon J. Hangeland, Todd J. Friends, Tamara Dejneka, Pratik Devasthale, Yolanda V. Caringal, Minsheng Zhang, Arthur M. P. Doweyko, Johan Malm, Andrei Sanin
  • Publication number: 20120220551
    Abstract: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 30, 2012
    Applicant: Eternity Bioscience Inc.
    Inventors: Baihua Hu, Kan He, Minsheng Zhang
  • Patent number: 7858658
    Abstract: Compounds of Formula (I), are provided where T is CHO, COR8, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substitutedalkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substitutedphenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused to Y when Y=C, or substituted diene fused to Y when Y=C; W, Y and Z are C, CR6 or N where at least one of W, Y or Z are C; R6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO2, or NR7; R7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R8 is lower alkyl, CF3, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: December 28, 2010
    Assignee: Wyeth LLC
    Inventors: Anthony Frank Kreft, Lynn Resnick, Scott Christian Mayer, George Diamantidis, Derek Cecil Cole, Boyd Lynn Harrison, Minsheng Zhang, Molly Hoke, Tingzhong Wang, Rocco John Galante